Skip to main content
Hauptrubriken
CME Facharzt-Training Webinare Zeitschriften Bücher e.Medpedia Podcast
Service
Jobbörse Info & Hilfe
Fachgebiete
Anästhesiologie Allgemeinmedizin Arbeitsmedizin Augenheilkunde Chirurgie Dermatologie Gynäkologie und Geburtshilfe HNO Innere Medizin Kardiologie Neurologie Onkologie und Hämatologie Orthopädie und Unfallchirurgie Pädiatrie Pathologie Psychiatrie Radiologie Rechtsmedizin Urologie Zahnmedizin
Themen
Klimawandel und Gesundheit Neues aus dem Markt COVID-19 Praxis und Beruf Seltene Erkrankungen GOÄ & EBM Panorama
Sammlungen
Kasuistiken Algorithmen & Infografiken Blickdiagnosen Arthropedia FlapFinder (für Dermatochirurgen) Videos Kongressberichterstattung Medizin für Apothekerinnen und Apotheker Für Ärztinnen und Ärzte in Weiterbildung Für Medizinstudierende
Erweiterte Suche
Anmelden
nach oben
Current Psychiatry Reports
Erschienen in: Current Psychiatry Reports 11/2018

01.11.2018 | Child and Adolescent Disorders (T Benton, Section Editor)

Attention-Deficit/Hyperactivity Disorder and Transitional Aged Youth

verfasst von: Timothy E. Wilens, Benjamin M. Isenberg, Tamar A. Kaminski, Rachael M. Lyons, Javier Quintero

Erschienen in: Current Psychiatry Reports | Ausgabe 11/2018

Einloggen, um Zugang zu erhalten

Abstract

Purpose of Review

Extensive research has been conducted on attention-deficit/hyperactivity disorder (ADHD) in children and adults; however, less is known about ADHD during the transition from childhood to adulthood. Transitional aged youth (TAY) with ADHD represents a particularly vulnerable population as their newfound independence and responsibility often coincides with the development of comorbid disorders. The purpose of this review is to provide an update on the evaluation, diagnosis, and treatment of TAY-ADHD.

Recent Findings

Recent studies discovering ADHD symptoms emerging in TAY call the classification of ADHD as a disorder necessarily developing in childhood into question. TAY-ADHD are also shown to be vulnerable to academic and social impairments, increased risky behavior, and comorbid psychiatric disorders. Due to the risk of stimulant diversion in TAY, providers are advised to take precaution when prescribing medication to this population. Recent studies demonstrating the efficacy of psychotherapy in conjunction with non-stimulant or extended release stimulant medication provide a feasible alternative.

Summary

This review highlights research on the course and evaluation of ADHD, impairments and comorbidities specific to TAY, and treatments tailored to address the unique challenges associated with TAY-ADHD.
Literatur
1.
Association AP. Diagnostic and statistical manual of mental health disorders, fifth edition (DSM-5). Arlington: American Psychiatric Publishing; 2013.CrossRef
2.
• Hechtman L, Swanson JM, Sibley MH, et al. Functional Adult Outcomes 16 Years After Childhood Diagnosis of Attention-Deficit/Hyperactivity Disorder: MTA Results. J Am Acad Child Adolesc Psychiatry. 2016;55(11):945–52 e2. This study compares the functional outcomes of those with childhood ADHD persisting and not persisting into adulthood, generally finding that more persistent symptomology is associated with worse outcomes.CrossRef
3.
Miesch M, Deister A. [Attention-deficit/hyperactivity disorder (ADHD) in adult psychiatry: Data on 12-month prevalence, risk factors and comorbidity]. Fortschr Neurol Psychiatr. 2018. Die Aufmerksamkeitsdefizit- und Hyperaktivitatsstorung (ADHS) in der Erwachsenenpsychiatrie: Erfassung der ADHS-12-Monatspravalenz, der Risikofaktoren und Komorbiditat bei ADHS.
4.
• Sasser TR, Kalvin CB, Bierman KL. Developmental trajectories of clinically significant attention-deficit/hyperactivity disorder (ADHD) symptoms from grade 3 through 12 in a high-risk sample: Predictors and outcomes. J Abnorm Psychol. 2016;125(2):207–19. This longitudinal study illuminates a pathway of childhood ADHD in which children who are more hyperactive, aggressive, or exposed to inconsistent or ineffective parental discipline are more likely to maintain clinically significant ADHD symptoms into adolescence and adulthood.CrossRef
5.
•• Caye A, Rocha TB, Anselmi L, et al. Attention-Deficit/Hyperactivity Disorder Trajectories From Childhood to Young Adulthood: Evidence From a Birth Cohort Supporting a Late-Onset Syndrome. JAMA Psychiatry. 2016;73(7):705–12. This longitudinal cohort study finds that a significant proportion of young adults manifest ADHD symptoms despite not displaying any symptoms as a child, calling the diagnostic requirement of a childhood onset of ADHD into questions.CrossRef
6.
Sibley MH, Rohde LA, Swanson JM, et al. Late-onset ADHD reconsidered with comprehensive repeated assessments between ages 10 and 25. Am J Psychiatry. 2018;175(2):140–9.CrossRef
7.
Quintero J, Vera R, Morales I, et al. Emotional intelligence as an Evolutive factor on adult with ADHD. J Atten Disord 2017:1087054716688251.
8.
• Gehricke JG, Kruggel F, Thampipop T, et al. The brain anatomy of attention-deficit/hyperactivity disorder in young adults - a magnetic resonance imaging study. PLoS One. 2017;12(4):e0175433. This article reviews the micro and macrostructural changes associated with a childhood diagnosis of ADHD.CrossRef
9.
Wilens T, Carrellas N, Biederman J. ADHD and substance misuse. In: Banaschewski T, editor. Oxford Textbook of Attention Deficit Hyperactivity Disorder. Oxford: Oxford University Press; 2016.
10.
Chan E, Fogler JM, Hammerness PG. Treatment of attention-deficit/hyperactivity disorder in adolescents: a systematic review. JAMA. 2016;315(18):1997–2008.CrossRef
11.
Uchida M, Spencer TJ, Faraone SV, et al. Adult outcome of ADHD: an overview of results from the MGH longitudinal family studies of Pediatrically and psychiatrically referred youth with and without ADHD of both sexes. J Atten Disord. 2018;22(6):523–34.CrossRef
12.
Fried R, Petty C, Faraone SV, et al. Is ADHD a risk factor for high school dropout? A Controlled Study. J Atten Disord. 2016;20(5):383–9.CrossRef
13.
Vargas TM, Flores MM, Beyer R. Coaches' perceptions and proposed solutions for challenging behaviors: implications for athletes with hidden disabilities. Int J Sports Sci Coach. 2015;10(5):783–96.CrossRef
14.
• Garner AA, Hansen AA, Baxley C, et al. The use of stimulant medication to treat attention-deficit/hyperactivity disorder in elite athletes: a performance and health perspective. Sports Med. 2018;48(3):507–12. This article provides an insightful review of the existing literature and arguments concerning the use of stimulant medications as a treatment for elite athletes with ADHD.CrossRef
15.
Fruchter E, Marom-Harel H, Fenchel D, et al. Functioning of young adults with ADHD in the military. J Atten Disord 2016:1087054716652478.
16.
Medical Standards for Appointment, Englistment, or Induction into the Military Service. In: Defense USDo, editor.: Office of the Under Secretary of Defense for Personnel and Readiness; 2018. p. 44.
17.
Chandra S, Biederman J, Faraone SV. Assessing the validity of the age at onset criterion for diagnosing ADHD in DSM-5. J Atten Disord 2016.
18.
Bunford N, Evans SW, Langberg JM. Emotion dysregulation is associated with social impairment among young adolescents with ADHD. J Atten Disord. 2018;22(1):66–82.CrossRef
19.
• Valero S, Bosch R, Corominas M, et al. Psychopathology and traffic violations in subjects who have lost their driving license. Compr Psychiatry. 2017;76:45–55. This study assessing psychopathologies potentially underlying traffic violations finds ADHD to be the strongest predictor of high risk driving.CrossRef
20.
Storebo OJ, Simonsen E. The association between ADHD and antisocial personality disorder (ASPD): a review. J Atten Disord. 2016;20(10):815–24.CrossRef
21.
McCabe SE, Veliz P, Wilens TE, et al. Adolescents' prescription stimulant use and adult functional outcomes: a National Prospective Study. J Am Acad Child Adolesc Psychiatry. 2017;56(3):226–33 e4.CrossRef
22.
Lichtenstein P, Halldner L, Zetterqvist J, et al. Medication for attention deficit-hyperactivity disorder and criminality. N Engl J Med. 2012;367(21):2006–14.CrossRef
23.
Katzman MA, Bilkey TS, Chokka PR, et al. Adult ADHD and comorbid disorders: clinical implications of a dimensional approach. BMC Psychiatry. 2017;17(1):302.CrossRef
24.
Jensen CM, Steinhausen HC. Comorbid mental disorders in children and adolescents with attention-deficit/hyperactivity disorder in a large nationwide study. Atten Defic Hyperact Disord. 2015;7(1):27–38.CrossRef
25.
Marangoni C, De Chiara L, Faedda GL. Bipolar disorder and ADHD: comorbidity and diagnostic distinctions. Curr Psychiatry Rep. 2015;17(8):604.CrossRef
26.
Daviss WB. Depressive DIsorders and ADHD. In: Daviss W, editor. Moodiness in ADHD. Cham: Springer; 2018. p. 91–109.CrossRef
27.
Tsang TW, Kohn MR, Efron D, et al. Anxiety in young people with ADHD: clinical and self-report outcomes. J Atten Disord. 2015;19(1):18–26.CrossRef
28.
Prevatt F, Dehili V, Taylor N, et al. Anxiety in college students with ADHD: relationship to cognitive functioning. J Atten Disord. 2015;19(3):222–30.CrossRef
29.
Brinkman WB, Epstein JN, Auinger P, et al. Association of attention-deficit/hyperactivity disorder and conduct disorder with early tobacco and alcohol use. Drug Alcohol Depend. 2015;147:183–9.CrossRef
30.
Yoshimasu K, Barbaresi WJ, Colligan RC, et al. Mediating and moderating role of depression, conduct disorder or attention-deficit/hyperactivity disorder in developing adolescent substance use disorders: a population-based study. PLoS One. 2016;11(6):e0157488.CrossRef
31.
Wilens TE, Morrison NR. The intersection of attention-deficit/hyperactivity disorder and substance abuse. Curr Opin Psychiatry. 2011;24(4):280–5.CrossRef
32.
Capusan AJ, Bendtsen P, Marteinsdottir I, et al. Comorbidity of adult ADHD and its subtypes with substance use disorder in a large population-based epidemiological study. J Atten Disord 2016.
33.
Groenman AP, Janssen TWP, Oosterlaan J. Childhood psychiatric disorders as risk factor for subsequent substance abuse: a meta-analysis. J Am Acad Child Adolesc Psychiatry. 2017;56(7):556–69.CrossRef
34.
Yeh TC, Wang SC, Chang YT, et al. Predictors of nicotine dependence in adolescents: symptoms of bipolar disorder and attention-deficit/hyperactivity disorder. J Child Adolesc Psychopharmacol. 2017;27(4):366–73.CrossRef
35.
Belendiuk KA, Pedersen SL, King KM, Pelham WE, Molina BS. Change over time in adolescent and friend alcohol use: Differential associations for youth with and without childhood attention-deficit/hyperactivity disorder (ADHD). Psychol Addict Behav. 2016;30(1):29–38.CrossRef
36.
Vogel T, Dom G, van de Glind G, et al. Is attention deficit/hyperactivity disorder among men associated with initiation or escalation of substance use at 15-month follow-up? A longitudinal study involving young Swiss men. Addiction. 2016;111(10):1867–78.CrossRef
37.
Estevez N, Dey M, Eich-Hochli D, Foster S, Gmel G, Mohler-Kuo M. Adult attention-deficit/hyperactivity disorder and its association with substance use and substance use disorders in young men. Epidemiol Psychiatr Sci. 2016;25(3):255–66.CrossRef
38.
Chang Z, Lichtenstein P, Halldner L, et al. Stimulant ADHD medication and risk for substance abuse. J Child Psychol Psychiatry. 2014;55(8):878–85.CrossRef
39.
• McCabe SE, Dickinson K, West BT, et al. Age of Onset, Duration, and Type of Medication Therapy for Attention-Deficit/Hyperactivity Disorder and Substance Use During Adolescence: A Multi-Cohort National Study. J Am Acad Child Adolesc Psychiatry. 2016;55(6):479–86. This multi-cohort national study examines the association between substance use and ADHD treatment onest, duration, and type in adolescence.CrossRef
40.
Hammerness P, Petty C, Faraone SV, et al. Do stimulants reduce the risk for alcohol and substance use in youth with ADHD? A secondary analysis of a prospective, 24-month open-label study of osmotic-release methylphenidate. J Atten Disord. 2017;21(1):71–7.CrossRef
41.
Schoenfelder EN, Sasser T. Skills versus pills: psychosocial treatments for ADHD in childhood and adolescence. Pediatr Ann. 2016;45(10):e367–e72.CrossRef
42.
Jensen CM, Amdisen BL, Jorgensen KJ, et al. Cognitive behavioural therapy for ADHD in adults: systematic review and meta-analyses. Atten Defic Hyperact Disord. 2016;8(1):3–11.CrossRef
43.
•• Philipsen A, Jans T, Graf E, et al. Effects of group psychotherapy, individual counseling, methylphenidate, and placebo in the treatment of adult attention-deficit/hyperactivity disorder: a randomized clinical trial. JAMA Psychiatry. 2015;72(12):1199–210. This randomized clinical trial provides compelling support that psychological interventions for ADHD are augmented when combined with stimulant pharmacotherapy.CrossRef
44.
• Sibley MH, Graziano PA, Kuriyan AB, et al. Parent-teen behavior therapy + motivational interviewing for adolescents with ADHD. J Consult Clin Psychol. 2016;84(8):699–712. This study evaluates the efficacy of the 'Supporting Teens’ Academic Needs Daily' program in conjunction with motivational interviewing as a treatment for adolescents with ADHD.CrossRef
45.
Sprich SE, Safren SA, Finkelstein D, et al. A randomized controlled trial of cognitive behavioral therapy for ADHD in medication-treated adolescents. J Child Psychol Psychiatry. 2016;57(11):1218–26.CrossRef
46.
McClain EK, Burks EJ. Managing attention-deficit/hyperactivity disorder in children and adolescents. Prim Care. 2015;42(1):99–112.CrossRef
47.
Vidal R, Castells J, Richarte V, et al. Group therapy for adolescents with attention-deficit/hyperactivity disorder: a randomized controlled trial. J Am Acad Child Adolesc Psychiatry. 2015;54(4):275–82.CrossRef
48.
Coghill DR, Banaschewski T, Soutullo C, et al. Systematic review of quality of life and functional outcomes in randomized placebo-controlled studies of medications for attention-deficit/hyperactivity disorder. Eur Child Adolesc Psychiatry. 2017;26(11):1283–307.CrossRef
49.
Catala-Lopez F, Hutton B, Nunez-Beltran A, et al. The pharmacological and non-pharmacological treatment of attention deficit hyperactivity disorder in children and adolescents: a systematic review with network meta-analyses of randomised trials. PLoS One. 2017;12(7):e0180355.CrossRef
50.
Li Y, Gao J, He S, et al. An evaluation on the efficacy and safety of treatments for attention deficit hyperactivity disorder in children and adolescents: a comparison of multiple treatments. Mol Neurobiol. 2017;54(9):6655–69.CrossRef
51.
Wilens TE, McKowen J, Kane M. Transitional-aged youth and substance use: teenaged addicts come of age. Contemp Pediatr [Internet]. 2013.
52.
Newcorn JH, Nagy P, Childress AC, et al. Randomized, double-blind, placebo-controlled acute comparator trials of Lisdexamfetamine and extended-release methylphenidate in adolescents with attention-deficit/hyperactivity disorder. CNS Drugs. 2017;31(11):999–1014.CrossRef
53.
Spencer TJ, Wilens TE, Biederman J, et al. Efficacy and safety of mixed amphetamine salts extended release (Adderall XR) in the management of attention-deficit/hyperactivity disorder in adolescent patients: a 4-week, randomized, double-blind, placebo-controlled, parallel-group study. Clin Ther. 2006;28(2):266–79.CrossRef
54.
Banaschewski T, Johnson M, Lecendreux M, et al. Health-related quality of life and functional outcomes from a randomized-withdrawal study of long-term lisdexamfetamine dimesylate treatment in children and adolescents with attention-deficit/hyperactivity disorder. CNS Drugs. 2014;28(12):1191–203.CrossRef
55.
Adler LA, Wilens T, Zhang S, Dittmann RW, D'Souza DN, Schuh L, et al. Atomoxetine treatment outcomes in adolescents and young adults with attention-deficit/hyperactivity disorder: results from a post hoc, pooled analysis. Clin Ther. 2012;34(2):363–73.CrossRef
56.
Weyandt LL, Oster DR, Marraccini ME, et al. Pharmacological interventions for adolescents and adults with ADHD: stimulant and nonstimulant medications and misuse of prescription stimulants. Psychol Res Behav Manag. 2014;7:223–49.CrossRef
57.
Wilens TE, Robertson B, Sikirica V, et al. A randomized, placebo-controlled trial of Guanfacine extended release in adolescents with attention-deficit/hyperactivity disorder. J Am Acad Child Adolesc Psychiatry. 2015;54(11):916–25 e2.CrossRef
58.
Hervas A, Huss M, Johnson M, et al. Efficacy and safety of extended-release guanfacine hydrochloride in children and adolescents with attention-deficit/hyperactivity disorder: a randomized, controlled, phase III trial. Eur Neuropsychopharmacol. 2014;24(12):1861–72.CrossRef
59.
Pauly V, Frauger E, Lepelley M, et al. Patterns and profiles of methylphenidate use both in children and adults. Br J Clin Pharmacol. 2018;
60.
•• Benson K, Flory K, Humphreys KL, et al. Misuse of stimulant medication among college students: a comprehensive review and meta-analysis. Clin Child Fam Psychol Rev. 2015;18(1):50–76. This meta-analytic review provides a useful summary of the recent research on stimulant misuse in college students, and identifies strategies for preventing and reducing misuse.CrossRef
61.
McCabe SE, Kloska DD, Veliz P, et al. Developmental course of non-medical use of prescription drugs from adolescence to adulthood in the United States: national longitudinal data. Addiction. 2016;111(12):2166–76.CrossRef
62.
Compton WM, Han B, Blanco C, Johnson K, Jones CM. Prevalence and Correlates of Prescription Stimulant Use, Misuse, Use Disorders, and Motivations for Misuse Among Adults in the United States. Am J Psychiatry. 2018;175(8):741–55.CrossRef
63.
Kilmer JR, Geisner IM, Gasser ML, et al. Normative perceptions of non-medical stimulant use: associations with actual use and hazardous drinking. Addict Behav. 2015;42:51–6.CrossRef
64.
• Wilens T, Zulauf C, Martelon M, et al. Nonmedical stimulant use in college students: association with attention-deficit/hyperactivity disorder and other disorders. J Clin Psychiatry. 2016;77(7):940–7. The findings of this study supply evidence that college-aged misusers of stimulants are more likely to have ADHD and are frequently attempting to self-medicate for under- and un-treated ADHD.CrossRef
65.
• Wilens TE, Carrellas NW, Martelon M, et al. Neuropsychological functioning in college students who misuse prescription stimulants. Am J Addict. 2017;26(4):379–87. In attempting to better elucidate the profiles of those who misuse stimulants, this study finds that those college stimulant misusers are more likely to evidence neuropsychological dysfunction than non-misusing peers.CrossRef
66.
Harrison AG, Armstrong IT. Development of a symptom validity index to assist in identifying ADHD symptom exaggeration or feigning. Clin Neuropsychol. 2016;30(2):265–83.CrossRef
67.
Colaneri N, Keim S, Adesman A. Physician practices to prevent ADHD stimulant diversion and misuse. J Subst Abus Treat. 2017;74:26–34.CrossRef
Metadaten
Titel
Attention-Deficit/Hyperactivity Disorder and Transitional Aged Youth
verfasst von
Timothy E. Wilens
Benjamin M. Isenberg
Tamar A. Kaminski
Rachael M. Lyons
Javier Quintero
Publikationsdatum
01.11.2018
Verlag
Springer US
Erschienen in
Current Psychiatry Reports / Ausgabe 11/2018
Print ISSN: 1523-3812
Elektronische ISSN: 1535-1645
DOI
https://doi.org/10.1007/s11920-018-0968-x

Weitere Artikel der Ausgabe 11/2018

Current Psychiatry Reports 11/2018 Zur Ausgabe

Complex Medical-Psychiatric Issues (M Riba, Section Editor)

Building Child and Adolescent Psychiatry Expertise in Ghana Through Training and Knowledge Dissemination: a Review of the Initial Collaboration Stages, Opportunities, and Challenges

Sex and Gender Issues in Behavioral Health (CN Epperson and L Hantsoo, Section Editors)

Sex Differences in Vulnerability to Prenatal Stress: a Review of the Recent Literature

Disaster Psychiatry: Trauma, PTSD, and Related Disorders (M J Friedman, Section Editor)

Posttraumatic Stress Disorder and Death From Suicide

Public Policy and Public Health (G Norquist, Section Editor)

Social Determinants of Mental Health: Where We Are and Where We Need to Go

Child and Adolescent Disorders (T Benton, Section Editor)

Autism Spectrum Disorder and Transition-Aged Youth

Disaster Psychiatry: Trauma, PTSD, and Related Disorders (MJ Friedman, Section Editor)

PTSD in Children Below the Age of 6 Years

Neu im Fachgebiet Psychiatrie

Demenzkranke durch Antipsychotika vielfach gefährdet

23.04.2024 Demenz Nachrichten

Wenn Demenzkranke aufgrund von Symptomen wie Agitation oder Aggressivität mit Antipsychotika behandelt werden, sind damit offenbar noch mehr Risiken verbunden als bislang angenommen.

Weniger postpartale Depressionen nach Esketamin-Einmalgabe

23.04.2024 Depression antepartal oder postpartal Nachrichten

Bislang gibt es kein Medikament zur Prävention von Wochenbettdepressionen. Das Injektionsanästhetikum Esketamin könnte womöglich diese Lücke füllen.

„Psychotherapie ist auch bei sehr alten Menschen hochwirksam!“

22.04.2024 DGIM 2024 Kongressbericht

Die Kombination aus Medikamenten und Psychotherapie gilt als effektivster Ansatz bei Depressionen. Das ist bei betagten Menschen nicht anders, trotz Besonderheiten.

Auf diese Krankheiten bei Geflüchteten sollten Sie vorbereitet sein

22.04.2024 DGIM 2024 Nachrichten

Um Menschen nach der Flucht aus einem Krisengebiet bestmöglich medizinisch betreuen zu können, ist es gut zu wissen, welche Erkrankungen im jeweiligen Herkunftsland häufig sind. Dabei hilft eine Internetseite der CDC (Centers for Disease Control and Prevention).

Update Psychiatrie

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.

Newsletter bestellen
Bildnachweise